The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process
Abstract
Advanced glycation end product (AGE) formation that occurs with aging and diabetes leads to the cross-linking of proteins and subsequent changes in the physicochemical properties of tissues. Cellular responses to AGE that lead to either pathological conditions or removal of AGE are mediated by a number of receptors that have been identified on various cell types such as macrophages, endothelial cells, and smooth-muscle cells. Mechanisms by which AGE affect the cardiovascular system include AGE cross-linking of long-lived proteins such as collagen and elastin and altered cellular responses. Alagebrium (3-phenacyl-4,5-dimethylthiazolium chloride, ALT-711) is the first drug in a new class of thiazolium therapeutic agents that break established AGE cross-links between proteins. In animal studies, alagebrium was effective in reducing large artery stiffness, slowing pulse-wave velocity, enhancing cardiac output, and improving left ventricular diastolic distensibility. In human studies to determine safety and efficacy, alagebrium was safe and well tolerated. In the first phase 2 clinical study, alagebrium improved arterial compliance in elderly patients with vascular stiffening. In two subsequent phase 2 clinical studies, one addressing diastolic heart failure and the other addressing systolic hypertension, alagebrium was effective in improving cardiac function and uncontrolled systolic blood pressure, particularly in more severely affected patients. Additional clinical studies to determine the utility of alagebrium in treating cardiovascular disorders associated with aging are in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of galectin-3 in diabetic nephropathy
Iacobini, C., Amadio, L., Oddi, G., Ricci, C., Barsotti, P., Missori, S., Sorcini, M., Di Mario, U., Pricci, F., & Pugliese, G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077402.95720.b4 · Cited by 99
Cited by
Townsend, R. R., Wilkinson, I. B., Schiffrin, E. L., Avolio, A. P., Chirinos, J. A., Cockcroft, J. R., Heffernan, K. S., Lakatta, E. G., McEniery, C. M., Mitchell, G. F., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000033 · Cited by 1,473
Cavalcante, J. L., Lima, J. A. C., Redheuil, A., & Al-Mallah, M. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.017 · Cited by 841
Arterial Aging: Is It an Immutable Cardiovascular Risk Factor?
Najjar, S. S., Scuteri, A., & Lakatta, E. G. (2005) · Hypertension · doi:10.1161/01.hyp.0000177474.06749.98 · Cited by 640
Ageing of the conduit arteries
Greenwald, S. (2007) · The Journal of Pathology · doi:10.1002/path.2101 · Cited by 637
Advanced glycation end products: Key players in skin aging?
Gkogkolou, P., & Böhm, M. (2012) · Dermato-Endocrinology · doi:10.4161/derm.22028 · Cited by 584
Metadata
- Authors
- BAKRIS, G., BANK, A., KASS, D., NEUTEL, J., PRESTON, R., & OPARIL, S.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12
- Volume
- 17
- Issue
- 12
- Pages
- S23-S30
- ISSN
- 0895-7061 (ISSN-L)
- OpenAlex
- W1967959058
- Cited by
- 210
- References
- 1
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. https://app.cochat.ai/papers/10.1016/j.amjhyper.2004.08.022
- The paper
- BAKRIS, G., BANK, A., KASS, D., NEUTEL, J., PRESTON, R., & OPARIL, S. (2004). Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. American Journal of Hypertension. https://doi.org/10.1016/j.amjhyper.2004.08.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.